The danger of substandard drugs in emerging markets: an assessment of basic product quality

Article Highlights

  • Tests show that legal but substandard drugs made in Africa and China have a noticeably higher failure rate

    Tweet This

  • While most drugs produced in emerging markets are of good quality, Indian and European generic drugs tend to be superior

    Tweet This

  • Companies in emerging markets that target their own population tend to be substandard

    Tweet This

The Danger of Substandard Drugs in Emerging Markets: An Assessment of Basic Product Quality

Download PDF
Demand for pharmaceuticals in emerging economies is increasing and pharmaceutical companies are supplying medications to new consumers. Many developing nations, including Kenya, Uganda and Nigeria have recently developed their own pharmaceutical production capabilities and the number of licensed producers in India and China has increased significantly.

In principle, expanded drug production is good for consumers since increased competition will cause prices to fall, thereby increasing drug access and patients' welfare. However, if the cheaper drugs are not bioequivalent (act in the same way in the body) to the approved innovator products which they are copying, this trend could cause significant harm to patients.

Most research on poor quality drugs has focused on counterfeit products or failed to draw a distinction between counterfeit products and legal substandard products (Bate et al., 2010b). It concludes that the burden of poor quality drugs is acute in African nations, but also extends in smaller quantities to most emerging markets. However, few studies have addressed the quality of the legitimate drugs sold in these markets. By removing counterfeit drugs, as far as is knowable, from the study sample and subjecting remaining samples to basic quality control tests, this study tentatively evaluates whether legally produced but substandard products are a threat to public health in emerging markets.

Roger Bate is the Legatum Fellow in Global Prosperity at AEI. Julissa Milligan is a research assistant at AEI.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate

 

Julissa
Milligan

What's new on AEI

Defeating ISIS: AEI experts weigh-in before the president’s address on Wednesday
image Degrading, defeating, and destroying the Islamic State
image Wealth Building Home Loan: Building wealth through homeownership and retirement savings
image The $3 iPhone
AEI on Facebook
Events Calendar
  • 15
    MON
  • 16
    TUE
  • 17
    WED
  • 18
    THU
  • 19
    FRI
Tuesday, September 16, 2014 | 5:00 p.m. – 6:00 p.m.
The Constitution as political theory

Please join us for the third-annual Walter Berns Constitution Day Lecture as James Ceasar, Harry F. Byrd Professor of Politics at the University of Virginia, explores some of the Constitution’s most significant contributions to political theory, focusing on themes that have been largely unexamined in current scholarship.

Wednesday, September 17, 2014 | 8:10 a.m. – Thursday, September 18, 2014 | 1:30 p.m.
Third international conference on housing risk: New risk measures and their applications

We invite you to join us for this year’s international conference on housing risk — cosponsored by the Collateral Risk Network and AEI International Center on Housing Risk — which will focus on new mortgage and collateral risk measures and their applications.

Thursday, September 18, 2014 | 2:15 p.m. – 3:00 p.m.
Speaker of the House John Boehner on resetting America’s economic foundation

Please join us as Speaker John Boehner (R-OH) delivers his five-point policy vision to reset America’s economy.

Friday, September 19, 2014 | 9:15 a.m. – 11:00 a.m.
Reforming Medicare: What does the public think?

Please join us as a panel of distinguished experts explore the implications of the report and the consumer role in shaping the future of Medicare.

No events scheduled this day.
No events scheduled today.
No events scheduled this day.
No events scheduled this day.